NANOBIOTIX completed a global offering raising approximately $100 million in gross proceeds through the full exercise of the underwriters' over-allotment option. The offering included 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. The company plans to allocate proceeds toward JNJ-1900 development (less than 10%), Nanoprimer and other platforms (50-60%), and general corporate needs (30-40%), with sufficient runway through 2029.

Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.

Nanobiotix, a late-clinical stage biotechnology company, announced the pricing of its global follow-on offering consisting of 225,373 ADSs in the U.S. at $38.98 per share and 1,959,289 ordinary shares plus 345,099 pre-funded warrants in Europe at €33.60 per share. The offering is expected to raise approximately €85.0 million in gross proceeds. The company plans to use net proceeds for advancing its Nanoprimer platform (50-60%), general corporate purposes (30-40%), and supporting JNJ-1900 development (less than 10%). The offering is supported by existing shareholders including Qatar Holding LLC and Invus.

Nanobiotix announced a temporary trading halt on Euronext Paris effective May 21, 2026, to facilitate the pricing and allocation confirmation of its global follow-on offering. The offering consists of a U.S. public offering of American Depositary Shares and an international offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other countries. Trading is expected to resume at approximately 3:30 p.m. Paris time.

Nanobiotix, a late-clinical stage biotechnology company, announced the launch of an approximately €75 million (~$87 million) global follow-on offering consisting of American Depositary Shares and Ordinary Shares in the U.S. and Europe. The company plans to allocate proceeds toward advancing its Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The offering is expected to price before U.S. market open on May 21, 2026.

Nanobiotix announced a global follow-on offering of approximately €75 million (~$87 million USD) comprising an ADS offering in the US and an offering of ordinary shares and pre-funded warrants to qualified investors in Europe and other countries. The proceeds will be allocated primarily to advancing the Nanoprimer platform (50-60%), general corporate needs (30-40%), and JNJ-1900 development (less than 10%). The offering is being coordinated by Jefferies, TD Cowen, and Stifel.

Nanobiotix, a late-clinical stage biotechnology company, announced the launch of an approximately €75 million (~$87 million) global follow-on offering consisting of American Depositary Shares and Ordinary Shares in the U.S. and Europe. The offering will be priced before U.S. market open on May 21, 2026, with net proceeds allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). Jefferies, TD Cowen, and Stifel are acting as global coordinators.

Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.

Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.

Nanobiotix presented preclinical data demonstrating that its nanoprimer technology improves systemic biodisponibility and reduces hepatic toxicity and inflammation when administered before LNP-delivered DNA immunotherapies in mouse models. The technology works by temporarily occupying hepatic clearance pathways to increase drug circulation and target tissue accumulation while reducing liver exposure.

Nanobiotix presented preclinical data at the 2026 AACR Annual Meeting demonstrating that its Nanoprimer platform, when administered before LNP-delivered DNA immunotherapy, improves systemic bioavailability, reduces hepatic toxicity, and mitigates inflammatory responses in mouse models. The company is pursuing both external collaborations and internal pipeline development for the Nanoprimer platform to address liver clearance challenges in advanced therapeutics.

Nanobiotix (NASDAQ: NBTX) denied media reports of a potential acquisition by Johnson & Johnson, clarifying that no takeover process is underway. The company reaffirmed its focus on advancing its cancer treatment pipeline, particularly its partnership with J&J for the radioenhancer NBTXR3. Shares rose 6.17% to $31.07 following the clarification, with the stock up 774.83% over the past 12 months.